Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-metastatic prostate cancer

- PMLiVE

Pfizer’s breast cancer drug palbociclib extends survival

Positive trial results for oncology treatment

- PMLiVE

Pfizer appoints comms head in Spain

Monica Piñuela is promoted

- PMLiVE

FDA backs heroin overdose treatment

Evzio comes in auto injector to be used by family members or carers

- PMLiVE

Merck KGaA and Pfizer collaborate on lupus

Companies team up with academics to research treatments for autoimmune disorder

- PMLiVE

Astellas uses animated bladder in campaign

Character in US advertisement for Myrbetriq constantly interrupts a woman with overactive bladder

- PMLiVE

MannKind’s inhaled insulin backed for US approval

Afrezza finally on course for FDA approval in diabetes after two rejections

- PMLiVE

Doctors criticise FDA over Lemtrada rejection

Say Sanofi/Genzyme’s MS drug should have been approved

- PMLiVE

Astellas sets up regenerative medicine unit

Will spearhead company's efforts in cell-based therapies

Novartis building

FDA panel rejects Novartis’ heart failure hope serelaxin

Decision follows EMA knock back earlier this year

- PMLiVE

Pfizer gains ground in cholesterol antibody chase

 Reports positive phase 2b data for its PCSK9 blocker

Novartis building

More bad news for Novartis on heart failure candidate

FDA reviewers recommend against approving serelaxin

- PMLiVE

Pfizer says Xalkori tops chemo as first line therapy

Superior progression free survival for lung cancer patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links